Tag: IVL
Interventional News’ top 10 most popular stories of April 2023
Several of Interventional News’ most read stories from April covered the topic of interventional oncology (IO)—its interrelation with immuno-oncology, a robot-assisted lung metastases treatment,...
AVS’s pulsatile IVL technology attracts an additional US$8.8 million to close...
AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its pulsatile intravascular lithotripsy (PIVL) therapy, has...
Interventional News’ top 10 most popular stories of March 2023
Interventional News’ most popular stories from March included those covering new embolization and radiofrequency ablation data presented at the Society of Interventional Radiology (SIR)...
Shockwave Medical announces US launch of new peripheral IVL catheter
Shockwave Medical today announced the full US commercial availability of the Shockwave L6 peripheral intravascular lithotripsy (IVL) catheter following clearance by the US Food...
Interventional News’ top 10 most popular stories of January 2023
Interventional News’ most popular stories in the opening month of 2023 included news of first enrolments in clinical studies of peripheral arterial disease (PAD)...
Interventional News Issue 86—June 2022 US Edition
Interventional News 86 Highlights:
Eyes on intravascular lithotripsy
The vascular biology behind endovascular therapies
Profile: Yasuaki Arai
CX: Transfemoral access takes centre stage at...
Interventional News Issue 86—June 2022 Edition
Interventional News 86 Highlights:
Eyes on intravascular lithotripsy
The vascular biology behind endovascular therapies
Profile: Yasuaki Arai
CX: Transfemoral access takes centre stage at...
Shockwave Medical and Genesis MedTech obtain regulatory approval in China for...
Shockwave Medical and Genesis MedTech Group announced today that they have successfully obtained approval from China’s National Medical Products Administration (NMPA) to market and...
Shockwave IVL maintains superiority to angioplasty in calcified peripheral disease at...
Shockwave Medical announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with intravascular lithotripsy (IVL) led to...
Shockwave Medical announces global launch of new peripheral IVL catheter
Shockwave Medical has announced the global commercial availability of the Shockwave M5+ peripheral intravascular lithotripsy (IVL) catheter after receiving both CE mark and US...
Shockwave Medical enrols first patient in Disrupt BTK II study for...
Shockwave Medical has announced the start of the Disrupt BTK II postmarket study to assess the safety, effectiveness and optimal clinical use of the...
CMS increases hospital outpatient payment for peripheral intravascular lithotripsy
Shockwave Medical has announced that, as part of the calendar year 2022 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule, the Centers for...
VIVA 2021: IVL “consistently” treats real-world calcium in multiple peripheral vessel...
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL; Shockwave Medical) performs “consistently well” across challenging peripheral vessels,...
